Prakt. Lékáren. 2017; 13(1e) [Interní Med. 2016; 18(5): 226-230]

Possibilities of IFN-free therapy of hepatitis C

Petr Husa, Petr Husa ml.
Klinika infekčních chorob Lékařské fakulty Masarykovy univerzity a Fakultní nemocnice Brno

Chronic hepatitis C therapy using Directly Acting Antivirals (DAA) has high efficacy (till 100 %), minimum contra-indications and extraordinarilyfavorable safety profile. Primarily, it is necessary to pay attention to drug-drug interactions. However they are well documented and successfullyresolvable already in general clinical practice. Current possibilities of interferon-free therapy represent combinations of sofosbuvir withother DAA or with ribavirin and combination of paritaprevir boosted by ritonavir + ombitasvir ± dasabuvir. Fixed combinaton of elbasvir andgrazoprevir is already available in some countries of the world.

Keywords: chronic hepatitis C, sofosbuvir, ledipasvir, velpatasvir, paritaprevir, ombitasvir, dasabuvir, elbasvir, grazoprevir

Published: April 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Husa P, Husa P. Possibilities of IFN-free therapy of hepatitis C. Praktické lékárenství. 2017;13(E-verze 1/17):.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. European Association for the Study of Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol, 2014; 61: p. 73-95. Go to original source... Go to PubMed...
    2. European Association for the Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol, 2015; 63: p. 199-236. Go to original source... Go to PubMed...
    3. European Association for the Study of Liver. EASL recommendations on treatment of hepatitis C 2015. Summary. Dostupné na: www.easl.eu/medias/cpg/HCV2016/Summary.pdf. Staženo 30.9.2016.
    4. AASLD recommendation for testing, managing, and treating hepatitis C. Dostupné na www.hcvguidelines.org. Staženo 15.8.2016.
    5. Urbánek P, Husa P, Šperl J, et al. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Klin mikrobiol inf lek 2015; 21(3): 83-98.
    6. University of Liverpool. Drug interactions charts. Dostupné na www.hep-druginteractions.com.
    7. HARVONI. Souhrn údajů o přípravku. Dostupné na: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/003850/WC500177995.pdf. Staženo 15.8.2016.
    8. SOVALDI. Souhrn údajů o přípravku. Dostupné na: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf. Staženo 15.8.2016.
    9. EPCLUSA. Souhrn údajů o přípravku. Dostupné na: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/004210/WC500211151.pdf. Staženo 15.8.2016.
    10. VIEKIRAX. Souhrn údajů o přípravku. Dostupné na: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/003839/WC500183997.pdf. Staženo 15.8.2016.
    11. EXVIERA. Souhrn údajů o přípravku. Dostupné na: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/003837/WC500182233.pdf. Staženo 15.8.2016.
    12. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med, 2014; 370: p. 1594-1603. Go to original source... Go to PubMed...
    13. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med, 2014; 370: p. 1983-1992. Go to original source... Go to PubMed...
    14. Wyles DL, Sulkowski MS, Eron JJ, et al. TURQUOISE-I: 94% SVR12 in HCV/HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin. Hepatology, 2014; 60: p. 1136A.
    15. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med, 2014; 370: p. 1604-1614. Go to original source... Go to PubMed...
    16. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment experienced patients with HCV genotype 1b infection. Gastroenterology, 2014; 147: p. 359-365. Go to original source... Go to PubMed...
    17. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med, 2014; 370: p. 1973-1982. Go to original source... Go to PubMed...
    18. Pol S, Reddy KR, Baykal T, et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. Hepatology, 2014; 60: p. 1129A. Go to original source...
    19. Urbánek P. Exviera, Viekirax. Gastroent Hepatol, 2015; 69: p. 75-80. Go to original source...
    20. ZEPATIER. Souhrn údajů o přípravku. Dostupné na: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/004126/WC500211235.pdf. Staženo 15.8.2016.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.